Furthermore, in patients with MDS or acute myeloid leukemia, TP53 mutation was reported to be associated with a better response rate to DNA methylation inhibitors in comparison to its absence (100% vs 41%, P < .001) [11]. The gene discussed is TP53; the disease is acute myeloid leukemia.